

4 on a current fund
last 24 months
across filed funds
| Vehicle | Filed | Target | Sold to date | Investors |
|---|---|---|---|---|
| GSR Ventures VIIIFiled to raise in 2021, with no closing reported yet. | 2021 | $550M | $0 | 0 |
| GSR 2021 Opportunities FundFiled to raise in 2021, with no closing reported yet. | 2021 | $250M | $0 | 0 |
| GSR Ventures VIII (AIV)Filed to raise in 2021, with no closing reported yet. | 2021 | $550M | $0 | 0 |
| GSR Ventures VIIFiled to raise in 2019, with no closing reported yet. | 2019 | $450M | $0 |
Amounts are Item 13 as filed: the target is the whole offering, and the amount sold is cumulative across amendments rather than a final close. The filing carries no per-investor amount, so a firm’s own cheque is not recoverable here.
5 partners are named across this firm’s filings, 4 of them on a fund it is deploying now.
| Partner | Activity | Categories | Board seats | Last 24mo |
|---|---|---|---|---|
| Richard Lim | Slowing | Biotech & pharma, Digital health, Consumer apps & internet | 13 | 1 |
Categories of GSR Ventures’s own portfolio companies, based on 13 with a verified or cited source.
| Firm | Shared boards | Companies |
|---|---|---|
| Cure Ventures | 13 | Alessa Therapeutics, Deep 6 AI, Gossamer Bio, KINSA, Loop Now Technologies, Medable, MobiSocial, PARATEK PHARMACEUTICALS, PIPER THERAPEUTICS, Rulai, Sparta Software, TRIDENT PHARMACEUTICALS, ZingBox |
| Omega Funds | 13 | Alessa Therapeutics, Deep 6 AI, Gossamer Bio, KINSA, Loop Now Technologies, Medable, MobiSocial, PARATEK PHARMACEUTICALS, PIPER THERAPEUTICS, Rulai, Sparta Software, TRIDENT PHARMACEUTICALS, ZingBox |
| Abingworth Bioventures | 1 | PARATEK PHARMACEUTICALS |
| 0 |
| GSR Ventures VII (AIV)Filed to raise in 2019, with no closing reported yet. | 2019 | $450M | $0 | 0 |
| GSR 2017 Opportunities Fund | October 2017 | $173M | $99M | 30 |
| GSR Ventures VIFiled to raise in 2017, with no closing reported yet. | 2017 | $325M | $0 | 0 |
| GSR Ventures VFiled to raise in 2015, with no closing reported yet. | 2015 | $150M | $0 | 0 |
| Allen Zhu | Quiet | None listed | 0 | 0 |
| James Ding | Quiet | None listed | 0 | 0 |
| Ryann Yap | Quiet | None listed | 0 | 0 |
| Yutong ZhangNot on the current fund | Quiet | None listed | 0 | 0 |
Activity is filed board seats in the last 24 months: 4+ Active, 2–3 Selective, 1 Slowing, none Quiet. A firm's tier totals its partners, so an active firm may be four partners with one seat each. It undercounts partners who invest without taking a board seat, and filings lag a closing by weeks, so Quiet means the paperwork is quiet, not the person.
Not a filing value: this is Lev’s own classification of each company, one company one vote regardless of how many of GSR Ventures’s partners are named on its board, shown only when we found a specific, checkable source. Companies with no source read as unclassified and are left out of the shares above.
| ARCH Venture Partners | 1 | Gossamer Bio |
| Emerging Infrastructure Capital Partners | 1 | ZingBox |
| ExSight | 1 | TRIDENT PHARMACEUTICALS |
| FYRFLY Venture Partners | 1 | Sparta Software |
| JMI Equity | 1 | Gossamer Bio |
| Kleiner Perkins | 1 | KINSA |
| Lingotto Innovation Ventures | 1 | Medable |
| Pillar VC | 1 | PIPER THERAPEUTICS |
| Playground Global | 1 | Sparta Software |
| Walden Catalyst Ventures | 1 | Medable |
| Westlake Biopartners | 1 | KINSA |
A shared board seat: a company where filings name a GSR Ventures partner and a partner at the other firm, both with a clean identity match. Not a claim either firm led or co-led the round, only that both are named on the same board.